专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010124163A3 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) NEUTRALIZING ANTIBODIES 审中-公开
标题翻译： GRANULOCYTE-MACROPHAGE COLONY-STIMULATING因子（GM-CSF）中和抗体
公开(公告)号：WO2010124163A3
公开(公告)日：2011-03-03
申请号：PCT/US2010032170
申请日：2010-04-23
申请人： THERACLONE SCIENCES INC , CHAN-HUI PO-YING , FREY STEVEN , GRANDEA ANDRES G , COX THOMAS C
发明人： CHAN-HUI PO-YING , FREY STEVEN , GRANDEA ANDRES G , COX THOMAS C
IPC分类号： C07K16/24 , A61K39/395 , A61P29/02 , A61P35/00
CPC分类号： C07K16/243 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The invention provides a GM-CSF neutralizing human monoclonal antibody, 1783J22, as well as methods of making and use thereof. The monoclonal antibody is further characterized by its ability to bind epitopes from GM-CSF proteins of multiple species.
摘要翻译：本发明提供GM-CSF中和人单克隆抗体1783J22，以及其制备和使用方法。单克隆抗体的特征还在于其能够结合来自多种物种的GM-CSF蛋白的表位。

2. 发明申请

WO2012030904A3 HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES 审中-公开
标题翻译：人类免疫缺陷病毒（HIV） - 抗精神病药物
公开(公告)号：WO2012030904A3
公开(公告)日：2012-05-31
申请号：PCT/US2011049880
申请日：2011-08-31
申请人： THERACLONE SCIENCES INC , SCRIPPS RESEARCH INST , INT AIDS VACCINE INITIATIVE , CHAN-HUI PO-YING , DOORES KATHERINE , HUBER MICHAEL , KAMINSKY STEPHEN , FREY STEVEN , OLSEN OLE , MITCHAM JENNIFER , MOYLE MATTHEW , PHOGAT SANJAY K , BURTON DENNIS R , WALKER LAURA MARJORIE , POIGNARD PASCAL RAYMOND GEORGES , KOFF WAYNE , SIMEK-LEMOS MELISSA DANIELLE DE JEAN DE ST MARCEL
发明人： CHAN-HUI PO-YING , DOORES KATHERINE , HUBER MICHAEL , KAMINSKY STEPHEN , FREY STEVEN , OLSEN OLE , MITCHAM JENNIFER , MOYLE MATTHEW , PHOGAT SANJAY K , BURTON DENNIS R , WALKER LAURA MARJORIE , POIGNARD PASCAL RAYMOND GEORGES , KOFF WAYNE , SIMEK-LEMOS MELISSA DANIELLE DE JEAN DE ST MARCEL
IPC分类号： A61K39/42 , C07K16/00
CPC分类号： C07K16/1063 , A61K39/21 , A61K2039/505 , C07K16/1045 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gpl20 are provided. Immunogens for generating anti-HIVl bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
摘要翻译：本发明提供了一种获得广泛中和抗体（bNab）的方法，包括从供体PBMC样品中筛选记忆B细胞培养物，以抵抗多种HIV-1物种的中和活性，克隆显示广泛中和活性的记忆B细胞; 并从该记忆B细胞培养物中拯救单克隆抗体。所得到的单克隆抗体的特征在于它们以天然或单体形式选择性地结合来自Env蛋白的表位的能力，以及抑制HIV-1物种从多个进化枝的感染的能力。提供了含有用于预防，诊断和治疗HIV感染的人单克隆抗HIV抗体的组合物。提供了通过使用来自gp120可变环内的保守区域的表位的免疫来产生这种抗体的方法。还提供了用于产生抗HIV1bNAB的免疫原。此外，提供了使用合适表位的疫苗接种方法。

3. 发明申请

WO2010107939A3 HUMAN IMMUNODEFICIENCY VIRUS (HIV) -NEUTRALIZING ANTIBODIES 审中-公开
标题翻译：人类免疫缺陷病毒（HIV） - 抗精神病药物
公开(公告)号：WO2010107939A3
公开(公告)日：2011-05-26
申请号：PCT/US2010027695
申请日：2010-03-17
申请人： THERACLONE SCIENCES INC , INT AIDS VACCINE INITIATIVE , SCRIPPS RESEARCH INST , CHAN-HUI PO-YING , MITCHAM JENNIFER , OLSEN OLE , FREY STEVEN , MOYLE MATTHEW , PHOGAT SANJAY K , BURTON DENNIS R , WALKER LAURA MARJORIE , POIGNARD PASCAL RAYMOND GEORGES , DE JEAN DE ST MARCEL SIMEK-LEMOS MELISSA DANIELLE , KOFF WAYNE
发明人： CHAN-HUI PO-YING , MITCHAM JENNIFER , OLSEN OLE , FREY STEVEN , MOYLE MATTHEW , PHOGAT SANJAY K , BURTON DENNIS R , WALKER LAURA MARJORIE , POIGNARD PASCAL RAYMOND GEORGES , DE JEAN DE ST MARCEL SIMEK-LEMOS MELISSA DANIELLE , KOFF WAYNE
IPC分类号： A61K39/118 , A61K39/39 , C07K16/10
CPC分类号： C07K16/1045 , A61K39/21 , A61K2039/505 , C07K16/1063 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-I species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-I species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gpl20 are provided. Immunogens for generating anti-HIV 1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
摘要翻译：本发明提供一种获得广泛中和抗体（bNab）的方法，包括筛选来自供体PBMC样品的记忆B细胞培养物，以对多种HIV-1物质进行中和活性，克隆显示广泛中和活性的记忆B细胞; 并从该记忆B细胞培养物中拯救单克隆抗体。所得单克隆抗体的特征在于它们以天然或单体形式选择性地结合来自Env蛋白的表位的能力，以及抑制多个进化枝的HIV-1物质的感染。提供了含有用于预防，诊断和治疗HIV感染的人单克隆抗HIV抗体的组合物。提供了通过使用来自gp120的可变环内的保守区域的表位进行免疫来产生这种抗体的方法。还提供了用于产生抗艾滋病毒1疫苗的免疫原。此外，提供了使用合适表位的疫苗接种方法。

4. 发明申请

WO2005019470A2 DETECTING AND PROFILING MOLECULAR COMPLEXES 审中-公开
标题翻译：检测和分析分子配合物
公开(公告)号：WO2005019470A2
公开(公告)日：2005-03-03
申请号：PCT/US2004025945
申请日：2004-08-10
申请人： ACLARA BIOSCIENCES INC , CHAN-HUI PO-YING , SINGH SHARAT , SALIMI-MOOSAVI HOSSEIN
发明人： CHAN-HUI PO-YING , SINGH SHARAT , SALIMI-MOOSAVI HOSSEIN
IPC分类号： C07K16/46 , C12N7/02 , C12Q20060101 , G01N33/53 , G01N33/542 , G01N33/566 , C12Q
CPC分类号： G01N33/566 , G01N33/542 , Y10S436/824
摘要： Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex.
摘要翻译：提供了用于检测样品（例如细胞或组织裂解物）中分子（特别是蛋白质）复合物形成的方法。在一个方面，提供了对复合物中的第一种蛋白质特异的切割探针和对复合物中的一种或多种第二蛋白质特异的一种或多种结合化合物。在结合后，诱导裂解探针产生活性物质，例如单线态氧，其仅在裂解探针的局部区域中裂解连接至结合化合物的分子标签。释放的分子标签与测定混合物分离并彼此分离以提供与复合物中存在的蛋白质的数量和类型相关的读数。

5. 发明申请

WO2005037071A3 RECEPTOR TYROSINE KINASE SIGNALING PATHWAY ANALYSIS FOR DIAGNOSIS AND THERAPY 审中-公开
标题翻译：受体酪氨酸激酶信号通路分析用于诊断和治疗
公开(公告)号：WO2005037071A3
公开(公告)日：2007-06-07
申请号：PCT/US2004033815
申请日：2004-10-13
申请人： MONOGRAM BIOSCIENCES INC , MUKHERJEE ALI , TANG MENGXIANG , PANNU HARPRIT S , CHAN-HUI PO-YING , SINGH SHARAT
发明人： MUKHERJEE ALI , TANG MENGXIANG , PANNU HARPRIT S , CHAN-HUI PO-YING , SINGH SHARAT
IPC分类号： G01N33/567 , A61B20060101 , A61K31/4745 , C12Q1/68 , G01N33/50 , G01N33/543 , G01N33/566 , G01N33/574 , G01N33/68 , G01N33/74
CPC分类号： G01N33/74 , G01N33/5041 , G01N33/57492 , G01N33/6893 , G01N2333/485
摘要： The invention provides a method for determining the activation status of receptor tyrosine kinase (RTK) pathways in either cell samples or patient samples by measuring receptor dimerization and relative amounts of protein-protein complexes or activated effector proteins that are characteristic of an RTK pathway. The invention also provides a method of using such status information to select patients responsive to pathway-specific drugs, and more particularly, to methods for measuring ErbB receptors and receptor complexes and using such information to select patients responsive to ErbB pathway-specific drugs. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more complexes formed in RTK activation. After binding, molecular tags are released and separated from the assay mixture for analysis.
摘要翻译：本发明提供了通过测量受体二聚化和RTK途径特征的蛋白质 - 蛋白质复合物或活化的效应物蛋白的相对量来确定细胞样品或患者样品中受体酪氨酸激酶（RTK）途径的激活状态的方法。本发明还提供了使用这种状态信息来选择对途径特异性药物有反应的患者的方法，更具体地，涉及用于测量ErbB受体和受体复合物的方法，并使用这些信息来选择对ErbB途径特异性药物有反应的患者。优选地，本发明的方法通过使用具有可释放分子标签的结合化合物组来实现，所述可释放分子标签对于在RTK活化中形成的一种或多种复合物的多种组分是特异性的。结合后，分离标签被释放并与测定混合物分离，用于分析。

6. 发明申请

WO03006947A3 CELL-SCREENING ASSAY AND COMPOSITION 审中-公开
标题翻译：细胞筛选测定和组成
公开(公告)号：WO03006947A3
公开(公告)日：2003-05-08
申请号：PCT/US0221339
申请日：2002-07-05
申请人： ACLARA BIOSCIENCES INC , SINGH SHARAT , CHAN-HUI PO-YING
发明人： SINGH SHARAT , CHAN-HUI PO-YING
IPC分类号： G01N33/50 , G01N33/58 , C12Q1/66 , C07H21/02 , C07H21/04 , C12N9/12 , C12P21/06 , G01N27/26
CPC分类号： G01N33/5023 , G01N33/5008 , G01N33/581
摘要： The present invention discloses methods for multiplexed cellular assays. The methods can be used for a simultaneous quantitation of transcription levels from multiple promoters, multiple drugs, or for monitoring effects on multiple protein-protein interactions. These methods make use of reporter gene constructs that couple a single reporter enzyme coding sequence with one or more promoter regions, and a set of probes that are subject to degradation by the reporter enzyme, producing a set of reporters that can be separated from each other by differences in their mobilities. Multiplexed assays are achieved by combining a set of cell populations, wherein each population contains a distinct reporter gene construct and a distinct probe. Various treatments are then carried out on the mixture of cells. Treatments that induce transcription from specific promoters will cause synthesis of the reporter enzyme in that particular cell population, leading to degradation of the corresponding probe. The generation of specific reporters is determined by electrophoresis, or other means of measuring mobility, and is correlated with an effect of the treatment on transcription from a defined promoter.
摘要翻译：本发明公开了用于多路复用细胞分析的方法。该方法可用于同时定量多种启动子，多种药物的转录水平，或用于监测对多种蛋白质 - 蛋白质相互作用的影响。这些方法利用将单个报道酶编码序列与一个或多个启动子区偶联的报道基因构建体和一组受到报道酶降解的探针，产生一组可以彼此分离的报道分子通过其流动性的差异。通过组合一组细胞群实现复合测定，其中每个群包含独特的报道基因构建体和独特的探针。然后对细胞混合物进行各种处理。诱导特定启动子转录的处理将引起该特定细胞群中报道酶的合成，导致相应探针的降解。特定报道分子的产生通过电泳或其他测量流动性的手段来确定，并与治疗对来自确定的启动子的转录的影响相关。

7. 发明申请

WO2004091384A3 ERBB SURFACE RECEPTOR COMPLEXES AS BIOMARKERS 审中-公开
标题翻译： ERBB表面受体复合物作为生物标志物
公开(公告)号：WO2004091384A3
公开(公告)日：2005-12-29
申请号：PCT/US2004009715
申请日：2004-03-30
申请人： ACLARA BIOSCIENCES INC , CHAN-HUI PO-YING , SALIMI-MOOSAVI HOSSEIN , SHI YINING , SINGH SHARAT , DUA RAJIV , MUKHERJEE ALI , PIDAPARTHI SAILAJA
发明人： CHAN-HUI PO-YING , SALIMI-MOOSAVI HOSSEIN , SHI YINING , SINGH SHARAT , DUA RAJIV , MUKHERJEE ALI , PIDAPARTHI SAILAJA
IPC分类号： A61B20060101 , C07K16/28 , C12N20060101 , C12Q3/00 , G01N33/542 , G01N33/543 , G01N33/574
CPC分类号： G01N33/57492 , C07K16/2863 , G01N33/542 , G01N2333/485 , G01N2800/52
摘要： The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.
摘要翻译：本发明涉及包含ErbB细胞表面膜受体的二聚体的患者样品中的新一类生物标志物。在一个方面，本发明包括通过将这样的病症与在患者样品，特别是固定组织样品中直接测量的一种或多种ErbB细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。另一方面，本发明包括通过将样本细胞中的ErbB细胞表面膜受体的一种或多种二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症状态的方法，包括存在或不存在癌前状态，存在或不存在癌症状态，癌症预后或对治疗的反应性。优选地，本发明的方法通过使用具有可释放分子标签的结合化合物来实现，所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。结合后，分离标签被释放并与测定混合物分离，用于分析。

8. 发明申请

WO2004092353A2 SURFACE RECEPTOR COMPLEXES AS BIOMARKERS 审中-公开
标题翻译：表面受体复合物作为生物标志物
公开(公告)号：WO2004092353A2
公开(公告)日：2004-10-28
申请号：PCT/US2004009717
申请日：2004-03-30
申请人： ACLARA BIOSCIENCES INC , CHAN-HUI PO-YING , SALIMI-MOOSAVI HOSSEIN , SHI YINING , SINGH SHARAT , DUA RAJIV , MUKHERJEE ALI , PIDAPARTHI SAILAJA
发明人： CHAN-HUI PO-YING , SALIMI-MOOSAVI HOSSEIN , SHI YINING , SINGH SHARAT , DUA RAJIV , MUKHERJEE ALI , PIDAPARTHI SAILAJA
IPC分类号： A61B20060101 , C07K16/28 , C12N20060101 , C12Q3/00 , G01N33/542 , G01N33/543 , G01N33/574 , C12N
CPC分类号： G01N33/57492 , C07K16/2863 , G01N33/542 , G01N2333/485 , G01N2800/52
摘要： The invention is directed to a new class of biomarker in patient samples comprising dimers of cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are release and separated from the assay mixture for analysis.
摘要翻译：本发明涉及包含细胞表面膜受体二聚体的患者样品中的新一类生物标志物。在一个方面，本发明包括通过将这样的病症与在患者样品，特别是固定组织样品中直接测量的一种或多种细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。另一方面，本发明包括通过将样本细胞中的一种或多种细胞表面膜受体的二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症的状态的方法，包括存在或不存在癌前状态，癌症状态的存在或不存在，癌症的预后或对治疗的反应性。优选地，本发明的方法通过使用具有可释放分子标签的结合化合物来实现，所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。结合后，将分子标签从测定混合物中释放并分离以进行分析。

9. 发明申请

WO2014179214A3 HUMAN RHINOVIRUS (HRV) ANITBODIES 审中-公开
标题翻译：人类RHINOVIRUS（HRV）病例
公开(公告)号：WO2014179214A3
公开(公告)日：2015-02-26
申请号：PCT/US2014035675
申请日：2014-04-28
申请人： CHAN-HUI PO-YING , SWIDEREK KRISTINE
发明人： CHAN-HUI PO-YING , SWIDEREK KRISTINE
IPC分类号： A61K39/00 , A61K39/12 , A61K39/125 , A61K39/42
CPC分类号： A61K39/125 , A61K39/00 , A61K45/06 , C07K16/1009 , C07K2317/21 , C07K2317/33 , C07K2317/76
摘要： The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.
摘要翻译：本发明提供了分离的完全人单克隆抗-HRV抗体，以及制备和使用这些抗体的方法。本发明的抗-HRV抗体预防或治疗患有HRV感染的受试者和相关疾病，包括但不限于感冒，鼻咽炎，痉挛，肺炎，细支气管炎，哮喘，慢性阻塞性肺病（COPD），鼻窦炎，细菌超感染和囊性纤维化。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式